73 related articles for article (PubMed ID: 17263628)
1. Antiviral activity of HIV type 1 protease inhibitors nelfinavir and indinavir in vivo is not influenced by P-glycoprotein activity on CD4+ T cells.
Sankatsing SU; Cornelissen M; Kloosterboer N; Crommentuyn KM; Bosch TM; Mul FP; Jurriaans S; Huitema AD; Beijnen JH; Lange JM; Prins JM; Schuitemaker H
AIDS Res Hum Retroviruses; 2007 Jan; 23(1):19-27. PubMed ID: 17263628
[TBL] [Abstract][Full Text] [Related]
2. HIV-protease inhibitors contribute to P-glycoprotein efflux function defect in peripheral blood lymphocytes from HIV-positive patients receiving HAART.
Lucia MB; Rutella S; Leone G; Vella S; Cauda R
J Acquir Immune Defic Syndr; 2001 Aug; 27(4):321-30. PubMed ID: 11468419
[TBL] [Abstract][Full Text] [Related]
3. Effect of protease inhibitor-containing regimens on lymphocyte multidrug resistance transporter expression.
Ford J; Meaden ER; Hoggard PG; Dalton M; Newton P; Williams I; Khoo SH; Back DJ
J Antimicrob Chemother; 2003 Sep; 52(3):354-8. PubMed ID: 12917239
[TBL] [Abstract][Full Text] [Related]
4. ATP binding cassette multidrug transporters limit the anti-HIV activity of zidovudine and indinavir in infected human macrophages.
Jorajuria S; Dereuddre-Bosquet N; Becher F; Martin S; Porcheray F; Garrigues A; Mabondzo A; Benech H; Grassi J; Orlowski S; Dormont D; Clayette P
Antivir Ther; 2004 Aug; 9(4):519-28. PubMed ID: 15456083
[TBL] [Abstract][Full Text] [Related]
5. P-Glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: potential for accelerated viral drug resistance?
Jones K; Bray PG; Khoo SH; Davey RA; Meaden ER; Ward SA; Back DJ
AIDS; 2001 Jul; 15(11):1353-8. PubMed ID: 11504956
[TBL] [Abstract][Full Text] [Related]
6. P-glycoprotein in blood CD4 cells of HIV-1-infected patients treated with protease inhibitors.
Bossi P; Legrand O; Faussat AM; Legrand M; Bricaire F; Marie JP; Agut H; Diquet B; Katlama C; Huraux JM; Calvez V
HIV Med; 2003 Jan; 4(1):67-71. PubMed ID: 12534962
[TBL] [Abstract][Full Text] [Related]
7. Differential effect of HIV-1 protease inhibitors on P-glycoprotein function in multidrug-resistant variants of the human CD4+ T lymphoblastoid CEM cell line.
Dupuis ML; Tombesi M; Sabatini M; Cianfriglia M
Chemotherapy; 2003 May; 49(1-2):8-16. PubMed ID: 12714803
[TBL] [Abstract][Full Text] [Related]
8. P-glycoprotein (ABCB1) activity decreases raltegravir disposition in primary CD4+P-gphigh cells and correlates with HIV-1 viral load.
Minuesa G; Arimany-Nardi C; Erkizia I; Cedeño S; Moltó J; Clotet B; Pastor-Anglada M; Martinez-Picado J
J Antimicrob Chemother; 2016 Oct; 71(10):2782-92. PubMed ID: 27334660
[TBL] [Abstract][Full Text] [Related]
9. Intracellular and plasma pharmacokinetics of nelfinavir and M8 in HIV-infected patients: relationship with P-glycoprotein expression.
Ford J; Cornforth D; Hoggard PG; Cuthbertson Z; Meaden ER; Williams I; Johnson M; Daniels E; Hsyu P; Back DJ; Khoo SH
Antivir Ther; 2004 Feb; 9(1):77-84. PubMed ID: 15040539
[TBL] [Abstract][Full Text] [Related]
10. Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments: clinical correlations.
Lafeuillade A; Solas C; Halfon P; Chadapaud S; Hittinger G; Lacarelle B
HIV Clin Trials; 2002; 3(1):27-35. PubMed ID: 11819183
[TBL] [Abstract][Full Text] [Related]
11. Drug resistance mutations in HIV-1-infected subjects during protease inhibitor-containing highly active antiretroviral therapy with nelfinavir or indinavir.
Yerly S; Rickenbach M; Popescu M; Taffe P; Craig C; Perrin L;
Antivir Ther; 2001 Sep; 6(3):185-9. PubMed ID: 11808753
[TBL] [Abstract][Full Text] [Related]
12. Saquinavir induces stable and functional expression of the multidrug transporter P-glycoprotein in human CD4 T-lymphoblastoid CEMrev cells.
Dupuis ML; Flego M; Molinari A; Cianfriglia M
HIV Med; 2003 Oct; 4(4):338-45. PubMed ID: 14525546
[TBL] [Abstract][Full Text] [Related]
13. Differences in durability of treatment with initial PI-based regimens.
Pérez-Elías MJ; Moreno A; Moreno S; Antela A; Dronda F; Muñoz V; Casado JL; Quereda C; Lopez D; Navas E
HIV Clin Trials; 2003; 4(6):391-9. PubMed ID: 14628282
[TBL] [Abstract][Full Text] [Related]
14. Prodrugs of HIV protease inhibitors-saquinavir, indinavir and nelfinavir-derived from diglycerides or amino acids: synthesis, stability and anti-HIV activity.
Gaucher B; Rouquayrol M; Roche D; Greiner J; Aubertin AM; Vierling P
Org Biomol Chem; 2004 Feb; 2(3):345-57. PubMed ID: 14747863
[TBL] [Abstract][Full Text] [Related]
15. Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial.
Abrams DI; Hilton JF; Leiser RJ; Shade SB; Elbeik TA; Aweeka FT; Benowitz NL; Bredt BM; Kosel B; Aberg JA; Deeks SG; Mitchell TF; Mulligan K; Bacchetti P; McCune JM; Schambelan M
Ann Intern Med; 2003 Aug; 139(4):258-66. PubMed ID: 12965981
[TBL] [Abstract][Full Text] [Related]
16. Diverse pattern of protease inhibitor resistance mutations in HIV-1 infected patients failing nelfinavir.
Svedhem V; Lindkvist A; Bergroth T; Knut L; Sönnerborg A
J Med Virol; 2005 Aug; 76(4):447-51. PubMed ID: 15977242
[TBL] [Abstract][Full Text] [Related]
17. Effects of nelfinavir and its M8 metabolite on lymphocyte P-glycoprotein activity during antiretroviral therapy.
Donahue JP; Dowdy D; Ratnam KK; Hulgan T; Price J; Unutmaz D; Nicotera J; Raffanti S; Becker M; Haas DW
Clin Pharmacol Ther; 2003 Jan; 73(1):78-86. PubMed ID: 12545146
[TBL] [Abstract][Full Text] [Related]
18. Influence of single-nucleotide polymorphisms in the multidrug resistance-1 gene on the cellular export of nelfinavir and its clinical implication for highly active antiretroviral therapy.
Zhu D; Taguchi-Nakamura H; Goto M; Odawara T; Nakamura T; Yamada H; Kotaki H; Sugiura W; Iwamoto A; Kitamura Y
Antivir Ther; 2004 Dec; 9(6):929-35. PubMed ID: 15651752
[TBL] [Abstract][Full Text] [Related]
19. Naive CD4+ T lymphocytes express high levels of Bcl-2 after highly active antiretroviral therapy for HIV infection.
Airò P; Torti C; Uccelli MC; Malacarne F; Palvarini L; Carosi G; Castelli F
AIDS Res Hum Retroviruses; 2000 Nov; 16(17):1805-7. PubMed ID: 11118066
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes.
Mootsikapun P; Chetchotisakd P; Anunnatsiri S; Boonyaprawit P
Antivir Ther; 2005; 10(8):911-6. PubMed ID: 16430196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
